Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
Advertisement

Related Content

Glaxo Consumer Finds Growth Groove Via Innovation, Acquisitions, Expansion
Glaxo Consumer Finds Growth Groove Via Innovation, Acquisitions, Expansion
Glaxo Consumer Finds Growth Groove Via Innovation, Acquisitions, Expansion
GSK Upbeat On Alli In EU As Global Consumer Sales Show Healthy Gains
GSK Upbeat On Alli In EU As Global Consumer Sales Show Healthy Gains
GSK eyes life after a patent cliff
GSK Spreads Smoking-Cessation Aids To Countries Serious About Quitting
GSK Touts Alli As Tip Of OTC Strength, Reaffirms Consumer Commitment
GSK Touts Alli As Tip Of OTC Strength, Reaffirms Consumer Commitment
New Products In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

PS102587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel